Drug intelligence / Profile preview

diazepam + lidocaine

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Epidural, Injection
01

Overview

Diazepam + lidocaine is a combination of two pharmaceutical agents used primarily to achieve regional anesthesia and analgesia, particularly in veterinary and procedural settings. Diazepam is a benzodiazepine that acts as a central nervous system depressant with anxiolytic, muscle relaxant, anticonvulsant, and sedative properties by enhancing the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors. Lidocaine is an amide-type local anesthetic that works by blocking voltage-gated sodium channels in neuronal membranes, thereby inhibiting nerve impulse conduction and producing localized numbness or loss of sensation. When administered together—such as via epidural injection—the combination provides both rapid onset neural blockade from lidocaine’s local anesthetic action and prolonged analgesic effects due to diazepam’s central modulation[9]. This mixture has been shown to produce longer-lasting analgesia than lidocaine alone without significant adverse effects on vital signs or blood parameters[9].

02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)

Beyond the preview

Go deeper on diazepam + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diazepam + lidocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call